Summit Wealth Group LLC Takes $66,000 Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Summit Wealth Group LLC purchased a new position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 40,000 shares of the biopharmaceutical company’s stock, valued at approximately $66,000.

Several other large investors also recently modified their holdings of the stock. BOKF NA acquired a new stake in Esperion Therapeutics during the 2nd quarter valued at $26,000. Traphagen Investment Advisors LLC bought a new position in Esperion Therapeutics in the 3rd quarter valued at $27,000. Xponance Inc. bought a new stake in shares of Esperion Therapeutics during the second quarter worth $28,000. Sivia Capital Partners LLC acquired a new stake in Esperion Therapeutics in the second quarter worth about $44,000. Finally, National Bank of Canada FI boosted its stake in shares of Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,225 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ESPR has been the subject of a number of recent research reports. StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Needham & Company LLC decreased their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. Finally, HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Tuesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Esperion Therapeutics has an average rating of “Hold” and an average price target of $8.17.

Esperion Therapeutics Stock Up 1.4 %

NASDAQ:ESPR opened at $2.15 on Tuesday. The business has a 50 day moving average price of $1.97 and a two-hundred day moving average price of $2.14. The company has a market cap of $423.64 million, a P/E ratio of -3.36 and a beta of 0.96. Esperion Therapeutics, Inc. has a twelve month low of $1.15 and a twelve month high of $3.40.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.